# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001213900-26-033064
Filing Date
2026-03-24
Accepted
2026-03-23 17:48:54
Documents
105
Period of Report
2025-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | ANNUAL REPORT | ea0281719-10k_polaryx.htm iXBRL | 10-K | 1489388
2 | DESCRIPTION OF THE COMPANY'S SECURITIES | ea028171901ex4-2.htm | EX-4.2 | 38641
3 | ADDENDUM #2 TO CONSULTANCY AGREEMENT, DATED MARCH 23, 2026, BY AND BETWEEN MSTON | ea028171901ex10-13.htm | EX-10.13 | 5507
4 | INSIDER TRADING POLICY | ea028171901ex19-1.htm | EX-19.1 | 82768
5 | CERTIFICATION | ea028171901ex31-1.htm | EX-31.1 | 9241
6 | CERTIFICATION | ea028171901ex31-2.htm | EX-31.2 | 9238
7 | CERTIFICATION | ea028171901ex32-1.htm | EX-32.1 | 5195
8 | INCENTIVE COMPENSATION CLAWBACK POLICY | ea028171901ex97-1.htm | EX-97.1 | 25656
9 | GRAPHIC | ea028171901_img1.jpg | GRAPHIC | 338306
10 | GRAPHIC | ea028171901_img2.jpg | GRAPHIC | 359369
11 | GRAPHIC | ea028171901_img3.jpg | GRAPHIC | 226688
12 | GRAPHIC | ea028171901_img4.jpg | GRAPHIC | 63929
13 | GRAPHIC | ea028171901_img5.jpg | GRAPHIC | 232152
14 | GRAPHIC | ea028171901_img6.jpg | GRAPHIC | 227704
15 | GRAPHIC | ea028171901_img7.jpg | GRAPHIC | 293687
16 | GRAPHIC | ea028171901_img8.jpg | GRAPHIC | 91303
17 | GRAPHIC | ea028171901_img9.jpg | GRAPHIC | 214579
18 | GRAPHIC | ea028171901_img10.jpg | GRAPHIC | 183669
19 | GRAPHIC | ea028171901_img11.jpg | GRAPHIC | 248331
20 | GRAPHIC | ea028171901_img12.jpg | GRAPHIC | 366038
21 | GRAPHIC | ea028171901_img13.jpg | GRAPHIC | 206014
22 | GRAPHIC | ea028171901_img14.jpg | GRAPHIC | 116058
23 | GRAPHIC | ea028171901_img15.jpg | GRAPHIC | 671914
24 | GRAPHIC | ea028171901_img16.jpg | GRAPHIC | 126872
25 | GRAPHIC | ea028171901_img17.jpg | GRAPHIC | 622330
26 | GRAPHIC | ea028171901_img18.jpg | GRAPHIC | 191325
27 | GRAPHIC | ea028171901_img19.jpg | GRAPHIC | 255421
28 | GRAPHIC | ea028171901_img20.jpg | GRAPHIC | 459993
29 | GRAPHIC | ea028171901_img21.jpg | GRAPHIC | 461005
30 | GRAPHIC | ea028171901_img22.jpg | GRAPHIC | 354026
31 | GRAPHIC | ea028171901_img23.jpg | GRAPHIC | 207055
32 | GRAPHIC | ea028171901_img24.jpg | GRAPHIC | 385796
33 | GRAPHIC | ea028171901_img25.jpg | GRAPHIC | 357365
34 | GRAPHIC | ea028171901_img26.jpg | GRAPHIC | 180640
35 | GRAPHIC | ea028171901_img27.jpg | GRAPHIC | 160704
36 | GRAPHIC | ea028171901_img28.jpg | GRAPHIC | 220551
37 | GRAPHIC | ea028171901_img29.jpg | GRAPHIC | 368625
38 | GRAPHIC | ea028171901_img30.jpg | GRAPHIC | 292412
39 | GRAPHIC | ea028171901_img31.jpg | GRAPHIC | 221921
40 | GRAPHIC | ea028171901_img32.jpg | GRAPHIC | 213235
41 | GRAPHIC | ea028171901_img33.jpg | GRAPHIC | 211788
42 | GRAPHIC | ea028171901_img34.jpg | GRAPHIC | 205068
43 | GRAPHIC | ea028171901_img35.jpg | GRAPHIC | 202748
44 | GRAPHIC | ea028171901_img36.jpg | GRAPHIC | 171332
45 | GRAPHIC | ea028171901_img37.jpg | GRAPHIC | 145192
46 | GRAPHIC | ea028171901_ex19-1img1.jpg | GRAPHIC | 6473
47 | GRAPHIC | ea028171901_ex97-1img1.jpg | GRAPHIC | 2435
| Complete submission text file | 0001213900-26-033064.txt |  | 30776746

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
48 | XBRL SCHEMA FILE | plyx-20251231.xsd | EX-101.SCH | 35179
49 | XBRL CALCULATION FILE | plyx-20251231_cal.xml | EX-101.CAL | 29270
50 | XBRL DEFINITION FILE | plyx-20251231_def.xml | EX-101.DEF | 131072
51 | XBRL LABEL FILE | plyx-20251231_lab.xml | EX-101.LAB | 301518
52 | XBRL PRESENTATION FILE | plyx-20251231_pre.xml | EX-101.PRE | 248386
109 | EXTRACTED XBRL INSTANCE DOCUMENT | ea0281719-10k_polaryx_htm.xml | XML | 398201

Mailing Address SOUTH TOWER, 140 E RIDGEWOOD AVENUE SUITE 415 PARAMUS NJ 07652
Business Address 140 EAST RIDGEWOOD AVENUE SUITE 415, SOUTH TOWER PARAMUS NJ 07652 201-940-7236
Polaryx Therapeutics, Inc. (Filer) CIK: 0002075320 (see all company filings)

EIN.: 000000000 | State of Incorp.: WY | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-43080 | Film No.: 26783579
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)